Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulumimab
- Development stage
- Phase 2
- Lead developer
- Sichuan Cancer Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sulumimab is an investigational monoclonal antibody described in clinical trial contexts (e.g., ChiCTR2600123343) as a conversion therapy for advanced gastric adenocarcinoma and gastroesophageal junction (GEJ) adenocarcinoma. It is evaluated in combination with the CAPOX chemotherapy regimen, immunonutrition, and probiotics to facilitate R0 resection in patients with severe lymph node metastasis or oligometastatic disease. Based on the trial design and therapeutic area, sulumimab likely functions as an immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) pathway. However, the name sulumimab is not found in official drug registries or international nonproprietary name (INN) lists, and the provided trial details correspond to studies involving serplulimab, suggesting this may be a variant spelling or synthetic identifier.
- Other names
- sulumimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sulumimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulumimab.